Influence of vaccination route on the efficacy of Aujeszky's disease deletion-mutant vaccine.
In order to compare the effect of the route of immunization on the efficacy of a modified live Aujeszky's disease (AD) vaccine, which had deletions in both thymidine kinase (TK-) and glycoprotein gIII genes (gpIII-), 20 six-week-old pigs were vaccinated by either the intramuscular (IM) (n = 10) or subcutaneous (SC) (n = 10) route. All the animals, including five non-vaccinated control animals, were challenged with virulent AD virus 22 days after vaccination. Four of five non-vaccinated animals died within 12 days after challenge. Although none of vaccinated animals died, three of animals in the SC group exhibited clinical signs, and average daily gains in the SC group were depressed. The animals in the IM group were not found to shed challenge virus, but those in the SC group shed the virus up to 9 days. Virus neutralizing antibody titers in the vaccinated animals were low or non-detectable by 21 days after vaccination. A glycoprotein gII (gpII) screening ELISA detected gpII antibody in all animals in the IM group. While, only 30% of animals in the SC group were positive by the same test. The results of this study indicate that TK-, gpIII modified live AD virus vaccine is effective against challenge with virulent AD virus; however, vaccination by the SC route reduced vaccine efficacy in comparison with IM route.
Hasebe
H
H
Department of Veterinary Science, University of Nebraska-Lincoln 68583-0905.
Osorio
F A
FA
Hogg
A
A
Liauw
H
H
Bartkoski
M J
MJ
Sugiyama
M
M
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001831:Body Temperature; D001835:Body Weight; D011558:Herpesvirus 1, Suid / Q000276:immunology* / Q000302:isolation & purification; D007273:Injections, Intramuscular / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000662:veterinary; D016296:Mutagenesis; D009500:Neutralization Tests; D011557:Pseudorabies / Q000517:prevention & control*; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*; D014611:Vaccination / Q000662:veterinary*; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014765:Viral Vaccines